By Kosaku Narioka
Takeda Pharmaceutical cut its annual earnings forecasts as impairment charges for discontinued drug research pushed the company into the red in the latest quarter.
The Japanese drugmaker said Thursday that it swung to a net loss of 11.8 billion yen, equivalent to $77.3 million, for the three months ended September, from net profit of Y92.0 billion in the year-earlier period. The result was worse than the Y65.2 billion net profit estimate in a poll of analysts by data provider Visible Alpha.
Takeda recorded impairment charges of about Y58 billion in its second quarter related to the cell-therapy research it discontinued as part of a strategic portfolio review.
For the fiscal year ending March, it projected revenue to decline 1.8% to Y4.500 trillion and net profit to increase 42% to Y153.00 billion. The company previously expected revenue of Y4.530 trillion and net profit of Y228.00 billion.
Second-quarter revenue dropped 5.4% to Y1.113 trillion. Sales of plasma-derived products declined 2.9% to Y256.6 billion, while sales of ulcerative colitis drug Entyvio rose 3.3% to Y246.7 billion.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
October 30, 2025 05:24 ET (09:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.